Not only is the general public afraid of talking about “B”, but many hepatitis B patients will also be prone to go into three blind spots, causing adverse effects on their bodies and lives. Blind spot one: fear of infection, do not marry the correct point of view: accept the regular hospital standard treatment, marriage and children is not a problem. There are three very important ways to spread hepatitis B: blood transmission, mother-to-child transmission and sexual transmission. The general daily contact such as shaking hands, eating, talking, etc. is not infectious. However, it does not mean that a person infected with hepatitis B cannot get married, and if they do, they will definitely transmit it to each other. Now there are several ways, one is the healthy party to take protective measures, such as playing hepatitis B vaccine, to produce antibodies, with full protection. Another way before marriage if one of the couple has a very high hepatitis B virus replication, it is the time for antiviral treatment, which can be used to bring down the amount of virus. If the vaccine is given, but no antibodies are produced or that the vaccine is not given, or in the case of a relatively high viral load, other measures are taken, such as condoms and the like. For the issue of having children, more than 90% of hepatitis B patients in China are infected through mother-to-child transmission or during early childhood. Vertical mother-to-child transmission mostly occurs during pregnancy when the hepatitis B virus infects the fetus through the placenta (intrauterine infection) or during delivery and from close contact after birth. Mothers with a high hepatitis B viral load are at increased risk of intrauterine infection. In the latter two cases, immunoglobulin + hepatitis B vaccination can be given immediately after the birth of the newborn to block mother-to-child transmission with a success rate of 90 to 95 percent. The second blind spot: fear of injury, only to protect the liver correct point: do not “treat the symptoms but not the root cause”, hepatitis B treatment anti-virus is the most critical. Many hepatitis B patients, regardless of the severity of their condition, always like to eat some “hepatoprotective drugs” for years and years, thinking that since they are hepatoprotective drugs, long-term adherence to the benefits of harm. In fact, if the use of liver-protective drugs is not appropriate, such as not allopathic, the course of treatment is too long, the dose is too large will be harmful. The so-called “hepatoprotective drugs” refer to drugs that can improve liver function, promote liver cell regeneration, and enhance the liver’s detoxification ability. The “hepatoprotective drugs” are actually generic drugs for various liver diseases, and mainly play a supplementary therapeutic role, not a fundamental treatment measure. If you are just a hepatitis B carrier, it is not appropriate to use these drugs. Although the liver protection and enzyme lowering drugs make the transaminases fall faster, but can not effectively inhibit the hepatitis B virus in the patient’s body, can be said to treat the symptoms but not the root cause. In the absence of a clear cause, the use of enzyme-lowering drugs may conceal the truth of the disease. Even if you have been diagnosed with chronic viral hepatitis B, simply lowering enzymes instead of antiviral will only create the illusion of normal transaminases and even delay treatment. Anti-viral treatment is the key to treating hepatitis B at its source. The Chinese Guide to Hepatitis B Prevention and Treatment clearly states that there are currently two major categories of regular antiviral treatment drugs: one is interferon; the other is oral antiviral drugs such as lamivudine and adefovir. Hepatitis B patients should insist on using drugs that can clearly reduce cirrhosis and liver cancer, with fewer side effects and less economic burden, during long-term treatment. Blind Area 3: Fear of drug resistance and no treatment Correct view: Drug resistance can be prevented and treated without excessive fear, and drug resistance can be actively managed by grasping the 24 weeks. Drug resistance is not a problem for hepatitis B treatment. There is absolutely no need for patients to refuse oral antiviral drug treatment because of the fear of drug resistance. By adhering to follow-up, hepatitis B patients’ doctors can detect the signs of drug resistance as early as possible and effectively prevent and manage drug resistance as early as possible. According to clinical experience, 24 weeks (six months) is a critical time point for treatment. At present, for drug resistance management, adding drugs is better than changing drugs, that is, when signs of drug resistance are found at 24 weeks, adding drugs without cross-resistance sites can not only “prevent the problem before it happens”, but also greatly improve the treatment effect. The treatment of chronic hepatitis B is a constant battle, and one should not be eager to win, otherwise one will not be able to achieve it quickly. The current recommendations for the course of oral nucleoside (acid) analogs in the Chinese Guidelines for the Prevention and Treatment of Hepatitis B are at least 24 months for patients with major triplets, and at least 30 months or more for patients with minor triplets for whom there is no clear indicator for discontinuation.